Literature DB >> 3930959

Tissue plasminogen activator (t-PA). Will it fulfill its promise?

S Sherry.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3930959     DOI： 10.1056/NEJM198510173131609

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  The effects of oral pretreatment with zofenopril, an angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig.

Authors:  R A Tio; C D de Langen; P A de Graeff; W H van Gilst; K J Bel; K G Wolters; P H Mook; J van Wijngaarden; H Wesseling
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

Review 2.  Back to the future: so what will fibrinolytic therapy offer your patients with myocardial infarction?

Authors:  J R Mitchell
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-12

3.  Future prospects in the treatment of venous disease.

Authors:  E F Bernstein
Journal:  World J Surg       Date:  1986-12       Impact factor: 3.352

4.  Crescentic glomerulonephritis: a possible complication of streptokinase treatment for myocardial infarction.

Authors:  N Murray; J Lyons; M Chappell
Journal:  Br Heart J       Date:  1986-11

Review 5.  [Antibody mediated thrombolysis. A new therapeutic principle].

Authors:  C Bode; W Kübler
Journal:  Klin Wochenschr       Date:  1989-07-03

Review 6.  Clinical disorders of fibrinolysis: a critical review.

Authors:  R B Francis
Journal:  Blut       Date:  1989-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.